Clinical Trial

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

Completed
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the real-world effectiveness and safety of neoadjuvant nivolumab combined with chemotherapy in Argentinian patients with resectable non-small cell lung cancer (NSCLC)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-19.
Status change: Enrolling by Invitation → Completed 2026-01-06
Trial Details
NCT Number NCT07141563
Lead Sponsor Bristol-Myers Squibb
Collaborators: Grupo Argentino Oncología Torácica (GAOT) - Asociación Argentina Oncología Clínica (AAOC)
Conditions Non-small Cell Lung Cancer (NSCLC)
Enrollment 70 participants
Start Date 2025-05-26
Primary Completion 2025-11-18 (estimated)
Study Completion 2025-11-18 (estimated)
Updated on ClinicalTrials.gov 2026-01-07